Table 3

Total treatment-emergent adverse events (intent-to-treat population, n = 119)

Adverse event

n (%)


'Flu-like' symptoms

170 (39.4)

Headache

84 (19.4)

Injection-site reaction

46 (10.6)

Gastrointestinal abnormalities

25 (5.8)

Pain

20 (4.6)

Anxiety

13 (3.0)

Infections

10 (2.3)

Hypersensitivity reaction

7 (1.6)

Cytopenia

7 (1.6)

Hepatic disorders

7 (1.6)

Vertigo

6 (1.4)

Upper respiratory tract infection

5 (1.1)

Tachycardia

4 (0.9)

Dysmenorrhoea

3 (0.7)

Other

25 (5.8)

Total

432 (100)


Lugaresi et al. BMC Neurology 2012 12:7   doi:10.1186/1471-2377-12-7

Open Data